Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02887495 · ClinicalTrials.gov registry record
The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)
A clinical trial of Scleroderma, sponsored by George Washington University.
- Completed
- Registry status
- 600
- Enrollment target
- 1
- Study location
NCT02887495: Completed study of Scleroderma, sponsored by George Washington University.
NCT02887495 is a study of Scleroderma that has completed, run by George Washington University. The registered enrollment target is 600 participants, above the 376-participant average among 23 other Scleroderma trials with a reported enrollment target (60% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02887495, a study of Scleroderma, has completed, sponsored by George Washington University.
- COMPLETED
- Registry status
- 600 participants
- Enrollment target
- 1
- Study location
Study Summary
The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies are invited to participate. This research may help us understand how to prevent and treat scleroderma and other diseases.
Conditions Studied
Study Locations (1)
District of Columbia
- Victoria K Shanmugam - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2014-07 |
| Est. Completion | 2022-02-02 |
What the finished NCT02887495 record still lists
NCT02887495 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 376-participant average among 23 other Scleroderma trials with a reported enrollment target (60% higher).
The record links to 1 condition, with Scleroderma appearing as the primary indexed condition, and to 0 interventions.
NCT02887495 reports a single indexed study location in District of Columbia.
Frequently Asked Questions
What is clinical trial NCT02887495 about?
NCT02887495 is a clinical study titled "The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)". The Scleroderma bioreposiTOry and Pathogenesis Study (STOP Scleroderma) will help researchers use clinical data and human biospecimens to investigate why scleroderma patients develop certain complications from their disease. Patients with confirmed scleroderma, raynauds or positive autoantibodies ar...
What is the current status of trial NCT02887495?
This trial is currently completed. The enrollment target is 600 participants. The study started on 2014-07. Estimated completion is 2022-02-02.
What conditions does trial NCT02887495 study?
This clinical trial studies the following conditions: Scleroderma.
Who is sponsoring clinical trial NCT02887495?
This trial is sponsored by George Washington University, which has 133 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02887495 being conducted?
This trial has 1 study location across District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scleroderma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02887495's enrollment target sits among peer trials
600 3rd of 23 higher than 21 of 23 other Scleroderma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Scleroderma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Rheumatology Diet Study
RECRUITING
-
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
RECRUITING
-
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RECRUITING · Phase 1
-
Platform Clinical Study for Conquering Scleroderma
RECRUITING · Phase 2
-
Scleroderma Registry & Repository at the Hospital for Special Surgery
RECRUITING
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia